CoChat

Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy

Open access
Kim, Samuel, Buchlis, George, Fridlender, Zvi G., Sun, Jing, Kapoor, Veena, Cheng, Guanjun, Haas, Andrew, Cheung, Hung Kam, Zhang, Xiamei, Corbley, Michael, Kaiser, Larry R., Ling, Leona, Albelda, Steven M. · 2008 · Cancer Research
Cited by 84

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Locally produced transforming growth factor-β (TGF-β) promotes tumor-induced immunosuppression and contributes to resistance to immunotherapy. This article explores the potential for increased efficacy when combining immunotherapies with TGF-β suppression using the TGF-β type I receptor kinase inhibitor SM16. Adenovirus expressing IFN-β (Ad.IFN-β) was injected intratumorally once in established s.c. AB12 (mesothelioma) and LKR (lung cancer) tumors or intratracheally in a Kras orthotopic lung tumor model. Mice bearing TC1 (lung cancer) tumors were vaccinated with two injections of adenovirus expressing human papillomavirus-E7 (HPV-E7; Ad.E7). SM16 was administered orally in formulated chow. Tumor growth was assessed and cytokine expression and cell populations were measured in tumors and spleens by real-time PCR and flow cytometry. SM16 potentiated the efficacy of both immunotherapies in each of the models and caused changes in the tumor microenvironment. The combination of SM16 and Ad.IFN-β increased the number of intratumoral leukocytes (including macrophages, natural killer cells, and CD8+ cells) and increased the percentage of T cells expressing the activation marker CD25. SM16 also augmented the antitumor effects of Ad.E7 in the TC1 flank tumor model. The combination did not increase HPV-E7 tetramer-positive CD8+ T cells in the spleens but did induce a marked increase in the tumors. Tumors from SM16-treated mice showed increased mRNA and protein for immunostimulatory cytokines and chemokines, as well as endothelial adhesion molecules, suggesting a mechanism for the increased intratumoral leukocyte trafficking. Blockade of the TGF-β signaling pathway augments the antitumor effects of Ad.IFN-β immune-activating or Ad.E7 vaccination therapy. The addition of TGF-β blocking agents in clinical trials of immunotherapies may increase efficacy. [Cancer Res 2008;68(24):10247–56

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-1494

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 84

Metadata

Authors
Kim, S., Buchlis, G., Fridlender, Z. G., Sun, J., Kapoor, V., Cheng, G., Haas, A., Cheung, H. K., Zhang, X., Corbley, M., Kaiser, L. R., Ling, L., & Albelda, S. M.
Venue
Cancer Research
Published
2008-12-15
Volume
68
Issue
24
Pages
10247-10256
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2143015936
Cited by
84
References
7
FWCI
2.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-1494
The paper
Kim, S., Buchlis, G., Fridlender, Z. G., Sun, J., Kapoor, V., Cheng, G., Haas, A., Cheung, H. K., Zhang, X., Corbley, M., Kaiser, L. R., Ling, L., & Albelda, S. M. (2008). Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene Therapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-1494

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.